Prostate specific antigen as a clinical biomarker for prostate cancer: What's the take home message?

Cancer Biology and Therapy

Volumn 4, Issue 4, 2005, Pages 377-381

  Leach, Fredrick S ^a   Koh, Moon S ^a   Chan, Yung W ^b   Bark, Samantha ^b   Ray, Robert ^c   Morton, Ronald A ^d   Remaley, Alan T ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c FlexSite Diagnostics   (United States)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Biomarker; Home testing; Prostate cancer; PSA; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; HOME CARE; HUMAN; MALE; OBSERVER VARIATION; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TREATMENT FAILURE;

EID: 25144436927     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.4.1648     Document Type: Article

References (53)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
2. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273:548-52.
3. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141:1076-83.
4. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317:909-16.
5. Dennis LK, Resnick MI. Analysis of recent trends in prostate cancer incidence and mortality. Prostate 2000; 42:247-52.
6. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS. Cancer surveillance series: Interpreting trends in prostate cancer-part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. JNCI 1999; 91:1017-24.
7. Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS. National trends in the epidemiology of prostate cancer, 1973 to 1994: Evidence for the effectiveness of prostate-specific antigen screening. Urology 1998; 52:444-8.
8. Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK. Temporal trends in rates of prostate cancer: Declining incidence of advanced stage disease, 1974 to 1994. J Urol 1997; 158:1427-30.
9. Smart CR. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer 1997; 80:1835-44.
10. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151:1283-90.
11. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristics curves. J Urol 1994; 152:2037-42.
12. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147:841-5.
13. Collins GN, Martin PJ, Wynn-Davies A, Brooman PJ, O'Reilly PH. The effect of digital rectal examination, flexible cystoscopy and prostatic biopsy on free and total PSA, and the free-to-total prostate specific antigen ratio in clinical practice. J Urol 1997; 157:1744-7.
14. Diamandis EP, Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am 1997; 24:275-82.
15. Diamandis EP, Yu H. Prostate-specific antigen and lack of specificity for prostate cells. Lancet 1995; 345:1186.
16. Levesque M, Hu H, D'Costa M, Diamandis EP. Prostate-specific antigen expression by various tumors. J Clin Lab Anal 1995; 9:123-8.
17. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol 2004; 172:1297-301.
18. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003; 349:335-42.
19. Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM. Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology: Prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol 2002; 167:103-11.
20. Friedrich MJ. Issues in prostate cancer screening. JAMA 1999; 281:1573-8.
21. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280:975-80.
22. Brawley OW. Prostate carcinoma incidence and patient mortality: The effects of screening and early detection. Cancer 1997; 80:1857-63.
23. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996; 30:138-44.
24. McNaughton Collins M, Ransohoff DF, Barry MJ. Early detection of prostate cancer. Serendipity strikes again. JAMA 1997; 278:1516-9.
25. Hernandez J, Thompson IM. Prostate-specific antigen: A review of the validation of the most commonly used cancer biomarker. Cancer 2004; 101:894-904.
26. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol 2001; 165:1562-68.
27. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 1997; 277:1445-51.
28. Game X, Vincendeau S, Palascak R, Milcent S, Fournier R, Houlgatte A. Total and free serum prostate specific antigen levels during the first month of acute prostatitis. Eur Urol 2003; 43:702-5.
29. Okada K, Kojima M, Naya Y, Kamoi K, Yokoyama K, Takamatsu T, Mild T. Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. Urology 2000; 55:892-8.
30. Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GH, Schellhammer PF, Bruskewitz R, Matsumoto AM, Harrison LH, Fuselier HA, Walsh P, Roy J, Andriole G, Resnick M, Waldstreicher J. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000; 163:13-20.
31. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994; 152:1163-7.
32. Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, Benson MC. PSA density (PSAD). Role in patient evaluation and mangement. Urol Clin North Am 1993; 20:653-63.
33. Nishiya M, Miller GJ, Lookner DH, Crawford ED. Prostate specific antigen density in patients with histologically proven prostate carcinoma. Cancer 1994; 74:3002-9.
34. Oesterling JE, Jacobsen SJ, Cooner WH. The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol 1995; 153:1160-1163.
35. Bhanot S, Gopalakrishnan R, Oliver RT. Post-biopsy rise in serum PSA: A potential tool for the dynamic evaluation of prostate cancer/pro static intraepithelial neoplasia (PIN). Cancer Biol and Therapy 2003; 2:67-70.
36. Colberg JW, Smith DS, Catalona WJ. Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng./ml. J Urol 1993; 149:507-9.
37. Stephan C, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 1997; 79:104-9.
38. Hayek OR, Noble CB, de la Taille A, Bagiella E, Benson MC. The necessity of a second prostate biopsy cannot be predicted by PSA or PSA derivatives (density or free:total ratio) in men with prior negative prostatic biopsies. Curr Opin Urol 1999; 9:371-5.
39. Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schwartz MK, Bruzek DJ, Morris DL, Sokoll LJ, Chan DW, Yeung KK, Partin AW, Allard WJ. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000; 163:1476-80.
40. el-Shirbiny AM. Prostate specific antigen. Adv Clin Chem 1994; 31:99-133.
41. Lundwall A. Characterization of the gene for prostate-specific antigen, a human glandular kallikrein. Biochem Biophys Res Commun 1989; 161:1151-9.
42. Daimandis EP, Yousef GM, Luo L-Y, Magklara A, Obiezu CV. The new human kallikrein gene family: Implications in carcinogenesis. Trends in Endocrinol Metab 2000; 11:54-60.
43. Harvey TJ, Hooper JD, Myers SA, Stephenson SA, Ashworth LK, Clements JA. Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J Biol Chem 2000; 275:37397-406.
44. Dong Y, Lee SO, Zhang H, Marshall J, Gao AC, Ip C. Prostate specific antigen expression is downregulated by selenium through disruption of androgen receptor signaling. Cancer Res 2004; 64:19-22.
45. Pang S, Dannull J, Kaboo R, Xie Y, Tso CL, Michel K, de Kernion JB, Belldegrun AS. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res 1997; 57:495-9.
46. Wolf DA, Schulz P, Fittler F. Transcriptional regulation of prostate kallikrein-like genes by androgen. Mol Endocrinol 1992; 6:753-62.
47. Luke MC, Coffey DS. Human androgen receptor binding to the androgen response element of prostate specific antigen. J Androl 1994; 15:41-51.
48. David A, Mabjeesh N, Azar I, Biton S, Engel S, Bernstein J, Romano J, Avidor Y, Waks T, Eshhar Z, Langer SZ, Lifschitz-Mercer B, Matzkin H, Rotman G, Toporik A, Savitsky K, Mintz L. Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel pro state-specific proteins. J Biol Chem 2002; 277:18084-90.
49. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR. Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 1996; 271:7043-51.
50. Seregni E, Botti C, Ballabio G, Bombardieri E. Biochemical characteristics and recent biological knowledge on prostate-specific antigen. Tumori 1996; 82:72-7.
51. Malm J, Lilja H. Biochemistry of prostate specific antigen, PSA. Scand J Clin Lab Invest 1995; 221:15-22.
52. Bjartell A, Malm J, Moller C, Gunnarsson M, Lundwell A, Lilja H. Distribution and tissue expression of semenogelin I and II in men as demonstrated by in situ hybridization and immunocyochemistry. J Androl 1996; 17-26.
53. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591-7.